The FDA has approved Gazyva® (obinutuzumab) for adults and children ages 2 and older with idiopathic nephrotic syndrome that began in childhood and is frequently relapsing (FRNS) or steroid-dependent (SDNS). More information coming soon. Please visit our Patient Navigation tool for support.
Stay informed with the latest developments, research breakthroughs, and stories in the world of rare kidney diseases. We are dedicated to providing up-to-date information and updates on our initiatives, events, and the ongoing battle against RKD. Whether you are a patient, caregiver, healthcare professional, or supporter, our goal is to keep you connected with the latest advancements and resources available in the fight against these challenging conditions.
Search
NephCure is a registered non-profit (501c3) tax-exempt charitable organization. EIN # 38-3569922.
© Copyright 2024 NephCure, Inc. All rights reserved worldwide. NephCure, and the logo, are federally registered trademarks of NephCure, Inc.
EN 
ES 